Breaking News

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

TFF Pharmaceuticals, Inc.

Business conference phone and webcast at 4:30 PM ET

FORT Worthy of, Texas, April 29, 2022 (World NEWSWIRE) — TFF Prescription drugs, Inc. (NASDAQ: TFFP), a clinical-phase biopharmaceutical firm concentrated on establishing and commercializing impressive drug merchandise primarily based on its patented Thin Film Freezing (TFF) technology system, right now announced that it will release its monetary effects and small business update for the first quarter of 2022 on Wednesday, Could 11, 2022, just after the shut of the U.S. monetary marketplaces.

Convention Call and Webcast Information

The Enterprise will host a conference contact on Wednesday, May 11, 2022, at 4:30 PM ET to review the medical, company and money highlights. A concern-and-response session with investors will observe management’s remarks. To participate in the convention get in touch with, both sign up for the webcast or dial a person of the adhering to quantities prior to the start out of the connect with:

Domestic Dial-In Amount: 1-844-825-9789

Worldwide Dial-In Variety: 1-412-317-5180

Conference ID: 10166801

The simply call will also be webcast stay and can be accessed on TFF Pharmaceuticals’ Website, or immediately at

Be sure to entry the Company’s web site at least 15 minutes ahead of the meeting to register, obtain, and set up any required audio application. The meeting contact will also be out there for replay for a person thirty day period on the Company’s web site in the Situations Calendar of the Investors part.

ABOUT TFF Pharmaceuticals

TFF Prescribed drugs, Inc. is a clinical-phase biopharmaceutical organization participating patented quick freezing know-how to create and remodel medications into potent dry powder formulations for better efficacy, protection and steadiness. The company’s versatile Slim Movie Freezing (TFF) know-how system has wide applicability to transform any drug, like vaccines, small and large molecules and biologics, into an classy dry powder highly advantageous for inhalation, with enhanced absorption so medications can also be delivered to the eyes, nose and topically to the pores and skin. TFF has two guide drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder and continues to extend its pipeline by collaborating with a wide array of pharmaceutical corporations, tutorial institutions and govt companions to revolutionize healthcare all over the globe. The TFF System is shielded by 120+ patents issued or pending in the U.S. and internationally. To understand additional about TFF Prescription drugs and its product candidates, stop by the Company’s web page at

Harmless HARBOR
This push launch contains forward-looking statements relating to TFF Prescription drugs, Inc., which includes the expectations for its ongoing progress of Niclosamide Inhalation Powder for the procedure of COVID-19 infection, Inhaled Tacrolimus and Voriconazole Powders and the positive aspects of the Company’s TFF system and the Company’s strategies to insert to its present pipeline of products candidates. Those ahead-seeking statements contain acknowledged and unfamiliar risks, uncertainties and other components that could bring about precise benefits to vary materially. Between those people factors are: (i) the danger that the Firm may perhaps not be in a position to effectively conclude clinical tests or obtain pre-current market approval of its Inhaled Niclosamide Tacrolimus or Voriconazole Powders or any of its dry powder product candidates, (ii) no drug products incorporating the TFF system has received Fda pre-sector approval or or else been incorporated into a business drug product or service, (iii) the Organization has no recent agreements or understandings with any huge pharmaceutical providers for the advancement of a drug solution incorporating the TFF Platform, (iv) the hazard that the Company will not be in a position to conclude a extended-expression commercial agreement with any third-get together, and (v) all those other challenges disclosed in the area “Risk Factors” included in the Company’s 2021 Yearly Report on Variety 10-K submitted with the SEC on March 24, 2022. TFF Prescription drugs cautions audience not to put undue reliance on any forward-looking statements. TFF Prescription drugs does not undertake, and specially disclaims, any obligation to update or revise these types of statements to replicate new instances or unanticipated occasions as they arise, besides as needed by regulation.

TFF Prescribed drugs Trader Relations Call:
Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

TFF Prescription drugs Media Make contact with:
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
[email protected]

Source: TFF Prescribed drugs, Inc.